Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		18 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Costs and expenses:
Noncash stock expense associated with in-licensing agreement	$ 0	$ 0	$ 16,578,000	$ 297,000	$ 16,875,000
Noncash compensation	127,091	0	236,289	0	236,289
Other research and development	1,433,711	15,940	3,133,960	15,940	3,164,243
Total research and development	1,560,802	15,940	19,948,249	312,940	20,275,532
General and administrative:
Noncash compensation	690,999	0	1,942,301	0	2,028,795
Other general and administrative	462,425	14,175	1,313,960	14,175	1,782,157
Total general and administrative	1,153,424	14,175	3,256,261	14,175	3,810,952
Total costs and expenses	2,714,226	30,115	23,204,510	327,115	24,086,484
Operating loss	(2,714,226)	(30,115)	(23,204,510)	(327,115)	(24,086,484)
Other (income) expense:
Interest income	(4,951)	0	(12,711)	0	(12,711)
Other income	0	0	(272,232)	0	(272,232)
Interest expense	228,585	0	676,843	0	683,940
Change in fair value of notes payable	(227,659)	0	(915,512)	0	(915,512)
Total other income	(4,025)	0	(523,612)	0	(516,515)
Consolidated net loss	(2,710,201)	(30,115)	(22,680,898)	(327,115)	(23,569,969)
Net loss attributable to noncontrolling interest	(247,962)	(1,510)	(8,067,916)	(16,405)	(8,103,913)
Net loss attributable to TG Therapeutics, Inc. and subsidiaries	$ (2,462,239)	$ (28,605)	$ (14,612,982)	$ (310,710)	$ (15,466,056)
Basic and diluted net loss per common share (in dollars per share)	$ (0.16)	$ (0.01)	$ (1.34)	$ (0.21)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	15,810,299	2,632,000	10,901,070	1,494,359